A detailed approach on multiple myeloma and its treatment

Multiple myeloma is a cancer formed by malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. The immune system is composed of several types of cells that work together to fight infections and other diseases. Lymphocytes are the main cell type of the immune system. There are 2 major types of lymphocytes: T cells and B cells. When B cells respond to an infection, they mature and change into plasma cells. Plasma cells make the antibodies that help the body attack and kill germs. Lymphocytes can be found in many areas of the body, such as lymph nodes, the bone marrow, the intestines, and the bloodstream. Plasma cells, however, are mainly found in the bone marrow. Bone marrow is the soft tissue inside some hollow bones. In addition to plasma cells, normal bone marrow has cells that make the different normal blood cells. When plasma cells become cancerous and grow out of control they can produce a tumor called a plasmacytoma. These tumors generally develop in a bone, but they are also rarely found in other tissues. If there is only a single plasma cell tumor, it is called an isolated plasmacytoma. When there is more than one plasma cell tumor, it is called ‘multiple myeloma’. There are lot of plasma cell abnormalities, but multiple myeloma causes severe bone pain, so here we covered detailed notes on the disease and its treatment strategies

Prevalence, awareness, treatment and control of hypertension among adults of Raipur city, Chhattisgarh, India: a cross sectional study

Background: Hypertension is prevalent all over the world. Usually it is readily detectable, easily treatable condition and if left untreated may leads to serious complications. In considerable proportion of cases the disease tends to be asymptomatic for prolonged time, hence also labelled as ‘Silent killer’. High blood pressure (BP) is a major risk factor for cardiovascular disease and better control can lead to prevention of 300,000 of the 1.5 million annual deaths from cardiovascular diseases in India. The objective of the study was to find the prevalence, awareness, treatment and control status of hypertension among adults of Raipur city.Methods: A community based cross sectional study was carried out in 768 subjects of age 25-59 years residing in Raipur city, Chhattisgarh, India. A predesigned, pretested questionnaire was used for data collection. To classify blood pressure JNC VII criteria was used.Results: The prevalence of hypertension was 29.0 %. Out of 223 hypertensive (223/768), 59.2% were aware about their hypertensive status, in them 76.9% were on treatment and 49.5% were under control.Conclusions: There was striking lack of awareness of the condition and a suboptimal rate of control among those treated. These finding emphasize public health importance of hypertension in Raipur city and there is urgent need to address this through targeted intervention

Design and Evaluation of Polyherbal Nanogel for The Treatment of Rheumatoid Arthritis

A typical autoimmune condition known as rheumatoid arthritis is linked to progressive impairment, systemic problems, early death, and socioeconomic expenses. Rheumatoid arthritis has no known cause, and the prognosis is uncertain. However, new therapies with better results have been developed as a result of breakthroughs in our knowledge of the disease's aetiology. The current therapeutic approach, which reflects this advancement, involves starting intensive therapy shortly as a diagnosis is made and escalating the medication in the goal of clinical response while being guided by an evaluation of the disease condition. The medicinal industry is not an alternative to the increasing paradigm of nanotechnology, which is evoking advancements in practically all technological sectors. It has long been utilised for artificial medicine production. The emphasis today is on conventional therapies, though. This study has a considerable application in the developing field of nanomedicine because it focuses upon the nanogel preparations of conventional drugs. As the risks and shortcomings of contemporary medicine become more obvious, herbal therapies are experiencing a comeback because they are viewed as a fair and well-balanced method of therapy. The effectiveness of herbal medicines in the treatment and management of disease is demonstrated by developments in analytical and clinical studies. Herbal treatments' primary drawback is their failure to dissolve and stabilize. Newer technological developments may be able to solve the issues with herbal remedies. Nano-formulations show how modern technology and herbal medicines interact. Consequently, herbal medications' increased stability, homogeneity, low toxicity, and strong drug encapsulation capacities make them a promising candidate for innovative drug delivery systems

Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling

Elevated levels of Mucin-16 (MUC16) in conjunction with a high expression of truncated O-glycans is implicated in playing crucial roles in the malignancy of pancreatic ductal adenocarcinoma (PDAC). However, the mechanisms by which such aberrant glycoforms present on MUC16 itself promote an increased disease burden in PDAC are yet to be elucidated. This study demonstrates that the CRISPR/Cas9-mediated genetic deletion of MUC16 in PDAC cells decreases tumor cell migration. We found that MUC16 enhances tumor malignancy by activating the integrin-linked kinase and focal adhesion kinase (ILK/FAK)-signaling axis. These findings are especially noteworthy in truncated O-glycan (Tn and STn antigen)-expressing PDAC cells. Activation of these oncogenic-signaling pathways resulted in part from interactions between MUC16 and integrin complexes (α4β1), which showed a stronger association with aberrant glycoforms of MUC16. Using a monoclonal antibody to functionally hinder MUC16 significantly reduced the migratory cascades in our model. Together, these findings suggest that truncated O-glycan containing MUC16 exacerbates malignancy in PDAC by activating FAK signaling through specific interactions with α4 and β1 integrin complexes on cancer cell membranes. Targeting these aberrant glycoforms of MUC16 can aid in the development of a novel platform to study and treat metastatic pancreatic cancer

Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic

Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: An international, multicenter, comparative cohort study

PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19–free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19–free surgical pathways. Patients who underwent surgery within COVID-19–free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19–free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score–matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19–free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION Within available resources, dedicated COVID-19–free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study.

PURPOSE: As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19-free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS: This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19-free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS: Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19-free surgical pathways. Patients who underwent surgery within COVID-19-free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19-free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score-matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19-free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION: Within available resources, dedicated COVID-19-free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Open Access

Dendritic cell CNS recruitment correlates with disease severity in EAE via CCL2 chemotaxis at the blood–brain barrier through paracellular transmigration and ERK activatio